Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Dhanvantri Jeevan Rekha's Revenue for the
three
months ended in Jun. 2026 was ₹78.0 Mil. Dhanvantri Jeevan Rekha's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹26.2 Mil.
Hence, Dhanvantri Jeevan Rekha's Receivables Turnover for the
three
months ended in Jun. 2026 was 2.98.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Dhanvantri Jeevan Rekha Receivables Turnover Related Terms
Dhanvantri Jeevan Rekha Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Dhanvantri Jeevan Rekha's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:531043 vs HCA, THC, EHC: Receivables Turnover Comparison
For the Medical Care Facilities subindustry, Dhanvantri Jeevan Rekha's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dhanvantri Jeevan Rekha Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dhanvantri Jeevan Rekha's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Dhanvantri Jeevan Rekha's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dhanvantri Jeevan Rekha (BOM:531043) has a Receivables Turnover of 2.98 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Dhanvantri Jeevan Rekha and its competitors. According to the industry distribution chart, Dhanvantri Jeevan Rekha ranks #217 out of 659 companies in the Healthcare Providers & Services industry, placing it in the top 32.9%.
Is Dhanvantri Jeevan Rekha's Receivables Turnover too high?
Dhanvantri Jeevan Rekha's current Receivables Turnover is 2.98. The Healthcare Providers & Services industry median Receivables Turnover is 7.96. Dhanvantri Jeevan Rekha's value of 2.98 is 62.6% below this industry median. Based on the distribution chart, Dhanvantri Jeevan Rekha ranks #217 out of 659 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Dhanvantri Jeevan Rekha has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dhanvantri Jeevan Rekha's Receivables Turnover compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Dhanvantri Jeevan Rekha ranks #217 out of 659 companies for Receivables Turnover. This puts Dhanvantri Jeevan Rekha in the upper half of its industry. The industry median Receivables Turnover is 7.96. Dhanvantri Jeevan Rekha's value of 2.98 is 62.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.96, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dhanvantri Jeevan Rekha's current Receivables Turnover of 2.98 is 62.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Dhanvantri Jeevan Rekha and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dhanvantri Jeevan Rekha's current Receivables Turnover is 2.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dhanvantri Jeevan Rekha stock overvalued right now?
Based on GuruFocus' analysis, Dhanvantri Jeevan Rekha (BOM:531043) is currently considered Fairly Valued. The stock's GF Value™ is ₹28.11, compared to a current price of ₹27.69 — trading 1.5% below its estimated fair value. The current Receivables Turnover is 2.98 and 62.6% below the Healthcare Providers & Services industry median of 7.96. Dhanvantri Jeevan Rekha's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Dhanvantri Jeevan Rekha (BOM:531043), the current Receivables Turnover is 2.98 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dhanvantri Jeevan Rekha (BOM:531043) Overvalued in 2026?
Based on GuruFocus' analysis, Dhanvantri Jeevan Rekha stock appears to be undervalued.
The current stock price of ₹27.69 is trading 1.5% below its estimated GF Value™ of ₹28.11.
GuruFocus considers Dhanvantri Jeevan Rekha to be Fairly Valued.
Key valuation signals for BOM:531043:
Receivables Turnover: 2.98
GF Value™: ₹28.11 vs. price of ₹27.69 (1.5% below fair value)
Industry Position: 62.6% below the Healthcare Providers & Services median (#217 of 659)
No single metric tells the full story. See the BOM:531043 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dhanvantri Jeevan Rekha Ltd is engaged in providing diagnostic and therapeutic services and has extended its scope of diagnostic and hospital services by providing a fully operational Cath Lab, catering to higher end needs of the cardiac patients including Angiography, Angioplasty, Pacemaker Implantation, Valvuloplasty etc. The hospital has expanded its services to include a wide range of specialties such as Cardiology, Neurology, Orthopedics, Radiology, Gastroenterology, General Surgery, Urology, and General Medicine.
70GF Score
Get the complete analysis for BOM:531043
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531043 has been successfully added to your 
